Photo by nci from unsplash
Survival among patients diagnosed with acute promyelocytic leukemia (APL) has significantly improved with the use of all‐trans retinoic acid and arsenic trioxide. However, the need for immediate diagnosis and access… Click to show full abstract
Survival among patients diagnosed with acute promyelocytic leukemia (APL) has significantly improved with the use of all‐trans retinoic acid and arsenic trioxide. However, the need for immediate diagnosis and access to specialized care and the cost associated with APL management can potentially act as barriers for disadvantaged patients. The influence of sociodemographic factors on the outcomes of patients with APL remains unclear.
Keywords:
acute promyelocytic;
promyelocytic leukemia;
diagnosed acute;
patients diagnosed;
survival
Journal Title: Cancer
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!